Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

Amgen’s 11.6% return over the past six months has outpaced the S&P 500 by 7.3%, and its stock price has climbed to $307.50 ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

The Supreme Court declined to review a petition filed by Novartis' Sandoz unit that challenged two of Amgen's patents on its blockbuster rheumatoid arthritis drug, Enbrel, meaning there won't be a ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. Amgen (NASDAQ: AMGN) ...